Rocketvax AG

Rocketvax AG

Implementing cutting-edge science in next-generation vaccine design that will improve people’s lives globally.

Founded 2020

Basel, Switzerland 6 employees Grant Total: $5.20M Biotechnology, Health Care +2

RocketVax is a Swiss-based startup specializing in the development of next-generation vaccines. The company boasts a strong foundation, drawing on the expertise of leading institutions in Switzerland and Germany. By forming strategic partnerships with renowned virologists and biochemists, RocketVax has diversified its portfolio, focusing on the creation of live-attenuated vaccines for infectious diseases such as Covid-19, cancer, and auto-immune disorders. Founded in 2020, RocketVax has already made significant strides in the biotechnology, healthcare, and pharmaceutical industries. The latest milestone for the company includes receiving a Fr.3.20M grant investment on 03 August 2021, with support from notable backers such as Innosuisse, University Hospital Basel, and the Canton of Basel-Stadt. RocketVax's innovative approach incorporates proprietary molecular biology technologies, paving the way for the development of novel vaccines. With a focus on addressing critical global health issues, including the ongoing battle against Covid-19, RocketVax's commitment to cutting-edge science positions it as a key player in the evolution of vaccine design. As the company continues to advance its pipeline of vaccine candidates, it stands poised to make a significant impact on global public health.

Funding Stage	Amount	Investors	Lead Investors	Date
Seed Round	Fr.2.00	-		03 Aug 2021
Grant	Fr.3.20M	3	Innosuisse, University Hospital Basel +1	03 Aug 2021
Debt Financing	Fr.2.00M	-		03 Aug 2021

Funding Stage

Amount

Investors

Lead Investors

Date

Seed Round

Fr.2.00

03 Aug 2021

Grant

Fr.3.20M

Innosuisse, University Hospital Basel +1

03 Aug 2021

Debt Financing

Fr.2.00M

03 Aug 2021

FAQ About Rocketvax AG

Implementing cutting-edge science in next-generation vaccine design that will improve people’s lives globally.

Rocketvax AG was founded in 2020.

Rocketvax AG is headquartered in Basel, Switzerland.

Rocketvax AG operates in Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on vaccine development, molecular technology, DNA-based technology and digital DNA design platform.

Rocketvax AG has approximately 6 employees.

Rocketvax AG has completed 3 funding rounds, raising a total of $5.20M. The latest funding stage is Grant.

Top alternatives and competitors to Rocketvax AG include Novavax, AdaptVac, Advaccine, The Duke Human Vaccine Institute, VBI Vaccines Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Rocketvax AG and Novavax are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Rocketvax AG

Funding Rounds & Investors (3)

Rocketvax AG Alternatives & Competitors

FAQ About Rocketvax AG